Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 20, 2006
Last updated: October 2, 2014
Last verified: October 2014

This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as monotherapy is safe and well tolerated.

Condition Intervention Phase
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: Everolimus
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Primary efficacy analysis of total kidney volume (mITT set, multiple imputation) [ Time Frame: Baseline, Month 24 ] [ Designated as safety issue: No ]
    Everolimus (RAD001) compared to placebo with respect to the change from baseline in total kidney volume at Month 12 and then at Month 24.

Secondary Outcome Measures:
  • Changes in mean cyst and parenchyma volumes assessed by magnetic resonance imaging between the first and last day on study medication for extension period [ Time Frame: Months 24, 36, 48 and 60 ] [ Designated as safety issue: No ]
    Changes from baseline at Month 24 in total cyst and parenchyma volumes measured by MRI, changes from baseline at Months 24, 36, 48 and 60 in renal function (as assessed by eGFR, serum creatinine, and urine protein/creatinine ratio), annual change rate in calculated GFR by MDRD formula (cGFR) over two years, changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), occurrence of end-stage renal disease (ESRD) and overall survival.

  • Changes in renal function were assessed by urinalysis from first day to last day on study medication. [ Time Frame: Months 24, 36, 48 and 60 ] [ Designated as safety issue: No ]
    Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1. The changes in renal function were analyzed via analysis of covariance (ANCOVA) with treatment, pre-transplant hepatitis C virus status and randomization eGFR as covariates. Based on these ANCOVA analyses, the least-squares mean and standard errors of change were reported.

  • Incidence of newly developing end-stage renal disease (ESRD) assessed by number of patients who require renal replacement therapy during the conduct of the trial [ Time Frame: Months 24, 36, 48 and 60 ] [ Designated as safety issue: No ]
    Incidence of newly developing end-stage renal disease (ESRD) assessed by number of patients who require renal replacement therapy during the conduct of the trial

  • Safety and tolerability of the study drug assessed by monitoring and recording of adverse events, serious adverse events, and all infections [ Time Frame: Months 24, 36, 48 and 60 ] [ Designated as safety issue: Yes ]
    Incidence and severity of AEs, SAEs, infections, neutropenia, leukopenia, thrombopenia, increased lipids, AE of special interest (assumed mTOR inhibitor class-related adverse events and ADPKD-associated complications); incidence of anemia and frequency of abnormal vital signs and laboratory parameters.

  • Changes in blood pressure between the first and last day on study medication assessed by blood pressure measurements at 10 timepoints [ Time Frame: Months 24, 36, 48 and 60 ] [ Designated as safety issue: No ]
    Changes in blood pressure between the first and last day on study medication assessed by blood pressure measurements at 10 timepoints

  • Extension study: Course of calculated GFR (mL/min/1.73 m2) from Month 24 to Month 60 (ITT set, observed cases) [ Time Frame: Months 24, 36, 48 and 60 ] [ Designated as safety issue: No ]
    The course of cGFR was summarized descriptively by visit for the ITT set and the ITT subset compri¬sing completers of the core study. Changes from baseline were calculated for each study visit and summarized descriptively. Changes from baseline were compared between the two treatment groups with an ANCOVA with factor treatment and covariate baseline. The annual change rate in calculated GFR by MDRD formula (cGFR) over five years was calculated. The annual change rate was calculated as the slope obtained via mixed effect linear model with a linear regression to cGFRs with time (in year) for each treatment group. Subgroups analyses were performed on patients with different cGFR values at baseline (≤50, >50, ≤60, >60, ≤70, >70 mL/min/1.73 m²). All analyses of safety variables were based on the safety set. The safety variables in the follow-up period were analyzed descriptively and summarized by treatment group.

Enrollment: 431
Study Start Date: December 2006
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus
Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
Drug: Everolimus
Other Name: certican
Placebo Comparator: Placebo
Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
Drug: Placebo
placebo comparator


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Clinical diagnosis of autosomal dominant polycystic kidney disease ADPKD
  2. Chronic kidney disease (CKD) stage II / III
  3. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility

Exclusion Criteria

  1. ADPKD patients with normal renal function
  2. ADPKD patients with CKD stage IV
  3. Patients with a history of subarachnoid bleeding
  4. Patients with a history of severe infections
  5. Patients with life-threatening urinary tract or cyst infection in the past
  6. Patients who have received any investigational drug within four weeks prior to baseline
  7. Patients who have been treated with any non-protocol immunosuppressive drug or treatment within one month prior to baseline

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00414440

Novartis Investigative Site
Innsbruck, Austria, INNSBRUCK
Novartis Investigative Site
Linz, Austria, A-4010
Novartis Investigative Site
Wien, Austria, 1090
Novartis Investigative Site
Brest, France, 29200
Novartis Investigative Site
Grenoble, France, 38043
Novartis Investigative Site
Nantes Cedex, France, 44035
Novartis Investigative Site
Paris cedex 15, France, 75015
Novartis Investigative Site
Toulouse Cedex 4, France, 31054
Novartis Investigative Site
Berlin, Germany, 13353
Novartis Investigative Site
Berlin, Germany, 10117
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Frankfurt am Main, Germany, 60596
Novartis Investigative Site
Freiburg, Germany, 79106
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Homburg, Germany, 66421
Novartis Investigative Site
Kiel, Germany, 24105
Novartis Investigative Site
Koeln, Germany, 51109
Novartis Investigative Site
Leipzig, Germany, 04103
Novartis Investigative Site
Lübeck, Germany, 23538
Novartis Investigative Site
Muenster, Germany, 48149
Novartis Investigative Site
Regensburg, Germany, 93053
Novartis Investigative Site
Würzburg, Germany, 97080
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
No publications provided by Novartis

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT00414440     History of Changes
Other Study ID Numbers: CRAD001ADE12, 2006-001485-16
Study First Received: December 20, 2006
Last Updated: October 2, 2014
Health Authority: United States: Food and Drug Administration
Germany: Bundesinstitut für Arzneimittel und Medizinproduke

Keywords provided by Novartis:
end-stage renal disease, ESRD, autosomal dominant polycystic kidney disease, ADPKD, everolimus

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Multicystic Dysplastic Kidney
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Congenital Abnormalities
Kidney Diseases, Cystic
Renal Insufficiency
Renal Insufficiency, Chronic
Urogenital Abnormalities
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 24, 2014